Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

Peripheral Spondyloarthritis Clinical Trial

Official title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Peripheral Spondyloarthritis

Status Completed

Clinical Trial Summary

The objective of this study was to evaluate the efficacy and safety of adalimumab 40 mg administered every other week (eow) subcutaneously (SC) compared to placebo for 12 weeks followed by open label (OL) safety and efficacy assessments in participants with non-ankylosing spondylitis (AS), non-psoriatic arthritis (PsA) active peripheral spondyloarthritis (SpA) who have had an inadequate response to >= 2 non-steroidal anti-inflammatory drugs (NSAIDs), or are intolerant to, or have a contraindication for, NSAIDs.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Peripheral Spondyloarthritis
• Spondylarthritis

• NCT number: NCT01064856
• Study type: Interventional
• Source: AbbVie
• Status: Completed
• Phase: Phase 3
• Start date: February 2010
• Completion date: May 2014